Other Central Nervous System Disorders - Pipeline Review, H2 2012

Global Markets Direct, August 2012, Pages: 70

Other Central Nervous System Disorders – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Other Central Nervous System Disorders - Pipeline Review, H2 2012', provides an overview of the Other Central Nervous System Disorders therapeutic pipeline. This report provides information on the therapeutic development for Other Central Nervous System Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Other Central Nervous System Disorders. 'Other Central Nervous System Disorders - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Other Central Nervous System Disorders.
- A review of the Other Central Nervous System Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Other Central Nervous System Disorders pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Other Central Nervous System Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Other Central Nervous System Disorders pipeline depth and focus of Other Central Nervous System Disorders therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Other Central Nervous System Disorders Therapeutic Products under Development, Key Players in Other Central Nervous System Disorders Therapeutics, Other Central Nervous System Disorders Pipeline Overview, Other Central Nervous System Disorders Pipeline, Other Central Nervous System Disorders Pipeline Assessment

2
List of Tables 6
List of Figures 6
Introduction 7
REPORT COVERAGE 7
Other Central Nervous System Disorders Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Other Central Nervous System Disorders 9
Other Central Nervous System Disorders Therapeutics under Development by Companies 11
Other Central Nervous System Disorders Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Discovery and Pre-Clinical Stage Products 18
Comparative Analysis 18
Other Central Nervous System Disorders Therapeutics – Products under Development by Companies 19
Other Central Nervous System Disorders Therapeutics – Products under Investigation by Universities/Institutes 20
Companies Involved in Other Central Nervous System Disorders Therapeutics Development 21
Quark Pharmaceuticals, Inc. 21
Vernalis plc 22
NPS Pharmaceuticals, Inc. 23
Bio-Link 24
Azevan Pharmaceuticals, Inc. 25
Other Central Nervous System Disorders – Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Combination Products 27
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
NPSP-156 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
IRAP Inhibitors - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
SRX251 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
SRX246 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Neuroprotection And Neural Regeneration Program - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Tacrolimus - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Dantrolene - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Naltrexone + Marijuana - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Aripiprazole - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Immune Globulin - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Prograf - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Mexiletine - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Methylphenidate - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Filgrastim + Chemotherapy - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Lenograstim + Chemotherapy - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Quinacrine - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Buspirone - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Desipramine - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Enoxaparin - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Idebenone - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Ketamine - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Teicoplanin - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Vancomycin - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
V81444 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
NT-KO-009 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
NT-KO-012 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Other Central Nervous System Disorders Therapeutics – Drug Profile Updates 59
Other Central Nervous System Disorders Therapeutics – Discontinued Products 61
Other Central Nervous System Disorders Therapeutics - Dormant Products 62
Other Central Nervous System Disorders – Product Development Milestones 63
Featured News & Press Releases 63
Nov 29, 2010: Takeda Applies For Change Of Dosage And Administration Of Leuplin For Treatment Of Central Precocious Puberty 63
Oct 29, 2010: AVANIR Receives FDA Approval For NUEDEXTA For Treatment Of Pseudobulbar Affect 63
Oct 19, 2010: MediciNova's Announces That MN-166 Program Recognized As One Of Windhover's Top 10 Neuroscience Projects To Watch 64
Sep 08, 2010: Hemispherx To Present New Retrovirus Data At First International Workshop On XMRV And Chronic Fatigue Syndrome 64
Jun 30, 2010: Oxygen Biotherapeutics' Oxycyte PFCE Decreases Mortality From Decompression Sickness In Preclinical Study 65
Jun 29, 2010: Alnylam Obtains Approval To Initiate Phase I Study With ALN-TTR01 In Patients With TTR-Mediated Amyloidosis 65
Jun 21, 2010: Sinapis Pharma Commences Phase I Trial Of Methamphetamine In Brain Injury And Stroke Patients 66
Jun 17, 2010: Stem Cell Therapeutics Continues Validation Review Of Modified REGENESIS Phase IIb Stroke Trial 67
May 26, 2010: EpiCept Achieves Targeted Patient Enrollment In Phase IIb Trial Of Epicept NP-1 For Treatment Of CPN 67
Apr 19, 2010: Prana Announces Publication Of New Analysis Of Clinical Trial In Journal Of Alzheimer's Disease 67
Appendix 69
Methodology 69
Coverage 69
Secondary Research 69
Primary Research 69
Expert Panel Validation 69
Contact Us 70
Disclaimer 70

List of Tables
Number of Products Under Development for Other Central Nervous System Disorders, H2 2012 9
Products under Development for Other Central Nervous System Disorders – Comparative Analysis, H2 2012 10
Number of Products under Development by Companies, H2 2012 11
Number of Products under Investigation by Universities/Institutes, H2 2012 13
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 14
Comparative Analysis by Late Stage Development, H2 2012 15
Comparative Analysis by Mid Clinical Stage Development, H2 2012 16
Comparative Analysis by Early Clinical Stage Development, H2 2012 17
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 18
Products under Development by Companies, H2 2012 19
Products under Investigation by Universities/Institutes, H2 2012 20
Quark Pharmaceuticals, Inc., H2 2012 21
Vernalis plc, H2 2012 22
NPS Pharmaceuticals, Inc., H2 2012 23
Bio-Link, H2 2012 24
Azevan Pharmaceuticals, Inc., H2 2012 25
Assessment by Monotherapy Products, H2 2012 26
Assessment by Combination Products, H2 2012 27
Assessment by Stage and Route of Administration, H2 2012 29
Assessment by Stage and Molecule Type, H2 2012 31
Other Central Nervous System Disorders Therapeutics – Drug Profile Updates 59
Other Central Nervous System Disorders Therapeutics – Discontinued Products 61
Other Central Nervous System Disorders Therapeutics – Dormant Products 62

List of Figures
Number of Products under Development for Other Central Nervous System Disorders, H2 2012 9
Products under Development for Other Central Nervous System Disorders – Comparative Analysis, H2 2012 10
Products under Development by Companies, H2 2012 11
Products under Investigation by Universities/Institutes, H2 2012 12
Late Stage Products, H2 2012 15
Mid Clinical Stage Products, H2 2012 16
Early Clinical Stage Products, H2 2012 17
Discovery and Pre-Clinical Stage Products, H2 2012 18
Assessment by Monotherapy Products, H2 2012 26
Assessment by Combination Products, H2 2012 27
Assessment by Route of Administration, H2 2012 28
Assessment by Stage and Route of Administration, H2 2012 29
Assessment by Molecule Type, H2 2012 30
Assessment by Stage and Molecule Type, H2 2012 31

Customers who bought this item also bought

• Bone Disorders – Pipeline Review, H1 2013
• Sleep Disorders – Pipeline Review, H1 2013
• Substance (Drug) Abuse – Pipeline Review, H1 2013
• The Neurotechnology Industry 2012 Report
• Drug Addiction – Pipeline Review, H1 2013
• Nausea – Pipeline Review, H1 2013
• Transdermal CNS Therapeutics: Products, Pipeline Candidates, Markets, Forecasts
• Pandemic Influenza – Pipeline Review, H1 2013
• Brain Tumor – Pipeline Review, H1 2013
• Smoking Cessation – Pipeline Review, H1 2013